BioSpace News Archive

Health Fidelity, Inc., a company that provides innovative technologies for the value-based care era, today announced it will showcase UPMC’s adoption of the HF360 risk adjustment suite, a payer/provider collaboration solution that leverages NLP and machine learning to drive risk adjustment improvements by coordinating health plan and health system actions, during a presentation on Thursday, September 13 at the annual RISE West Summit at 1:05 PM local time.

Letco Medical, L.L.C. (“Letco”), a leading supplier of quality compounding pharmacy products, supplies and equipment, in exclusive partnership with Sweetgrass GxP, a leader in providing regulatory services for compounding pharmacies, announces the launch of Letco’s Regulatory Solutions Program.

Bovie Medical Corporation, a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that it has completed the previously announced divestiture and sale of the Core business segment and the Bovie® brand to Symmetry Surgical for gross proceeds of $97 million in cash.

A spin-out company from the renowned Korea Advanced Institute of Science and Technology in Daejeon has been established to commercialize the revolutionary Holotomography (HT) microscopy developed there by Professor YongKeun (Paul) Park.

The Institute for Bioscience and Biotechnology Research (IBBR) has entered into two separate collaborations involving its polyphosphazene (PPZ) polymer platform.

Altasciences announced today that construction work has begun on the expansion of their ligand binding laboratory to meet the high demand for quality bioanalytical services. The additional space will include a fully-equipped, state-of-the-art lab dedicated to ligand binding and cell based assays.

Crucial Data Solutions, Inc. announces the release of TrialKit™ for Android on September 1st, making it the first fully-featured app for electronic data capture (EDC) and electronic participant reported outcomes (ePRO) on both iOS and Android devices.

Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited (“Telix”) (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).

The caregiver burden of family members is significantly reduced when a loved one is enrolled in a Program of All-Inclusive Care for the Elderly (PACE®), according to a new survey by the National PACE Association.

ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, announced today that it will be participating in Citi’s 13th Annual Biotech Conference in Boston on September 5th